Emergent BioSolutions
EBS
$3.40
Share price
2.72%
Change (1 day)
-88.93%
Change (1 year)
Categories
Revenue for Emergent BioSolutions (EBS)
Revenue in 2023 (TTM): $1.07 B
According to Emergent BioSolutions 's latest financial reports the company's current revenue (TTM) is $1.07 B. In 2022 the company made a revenue of $1.12 B a decrease over the years 2021 revenue that were of $1.79 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Emergent BioSolutions from 2004 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $1.07 B | -4.21% |
| 2022 | $1.12 B | -37.47% |
| 2021 | $1.79 B | 15.26% |
| 2020 | $1.55 B | 40.63% |
| 2019 | $1.10 B | 41.37% |
| 2018 | $0.78 B | 39.49% |
| 2017 | $0.56 B | 10.61% |
| 2016 | $0.50 B | -3.01% |
| 2015 | $0.52 B | 16.14% |
| 2014 | $0.45 B | 43.93% |
| 2013 | $0.31 B | 10.95% |
| 2012 | $0.28 B | 3.11% |
| 2011 | $0.27 B | -4.47% |
| 2010 | $0.28 B | 21.89% |
| 2009 | $0.23 B | 31.49% |
| 2008 | $0.17 B | -2.38% |
| 2007 | $0.18 B | 19.76% |
| 2006 | $0.15 B | 16.87% |
| 2005 | $0.13 B | 56.52% |
| 2004 | $83.49 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $77.94 B | 7,159.38% | 🇺🇸 USA |
 Merck MRK | $58.31 B | 5,330.85% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $35.34 B | 3,192.32% | 🇬🇧 UK |
 Soligenix SNGX | $0.99 M | -99.91% | 🇺🇸 USA |
 SIGA Technologies SIGA | $97.77 M | -90.89% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $3.25 M | -99.70% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $15.01 B | 1,298.71% | 🇮🇱 Israel |